← Back to Search

Behavioral Intervention

Health Advocate for Adolescent Liver Transplant Recipients (HEAL-Tx:ToC Trial)

N/A
Recruiting
Led By Sharad Wadhwani, MD, MPH
Research Sponsored by University of California, San Francisco
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patient has received a liver transplant >1 year ago
Be between 18 and 65 years old
Must not have
Non-English, non-Spanish speakers
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 180 days
Awards & highlights

Summary

"This trial is testing a new program called the Health Advocate for Liver Transplant (HEAL-Tx) Transition of Care Pilot. The program aims to help adolescents transition their care to adult transplant teams by

Who is the study for?
This trial is for adolescents and young adults who have had a liver transplant and are transitioning their care to adult transplant teams. It's designed to see if having a Health Advocate helps with this process.Check my eligibility
What is being tested?
The HEAL-Tx pilot tests the integration of a Health Advocate into the transplant team. This role includes coordinating treatment, helping with finances like taxi vouchers, and linking patients to community resources.See study design
What are the potential side effects?
Since this trial involves non-medical intervention by introducing a Health Advocate rather than medication or surgery, there are no direct medical side effects associated with it.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I had a liver transplant more than a year ago.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I do not speak English or Spanish.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~180 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 180 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Changes in patient experience
Secondary outcome measures
A qualitative assessment of patient and healthcare provider satisfaction with the Health Advocate intervention.
Change in medication adherence using MLVI
The quality of health advocate interactions with the participants, healthcare team, and community-based resources.

Trial Design

1Treatment groups
Experimental Treatment
Group I: InterventionExperimental Treatment1 Intervention
This is a single arm pilot intervention.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Health Advocate
2017
N/A
~40

Find a Location

Who is running the clinical trial?

University of California, San FranciscoLead Sponsor
2,528 Previous Clinical Trials
15,242,612 Total Patients Enrolled
American Society of TransplantationUNKNOWN
1 Previous Clinical Trials
24 Total Patients Enrolled
Sharad Wadhwani, MD, MPHPrincipal InvestigatorUniversity of California, San Francisco
2 Previous Clinical Trials
510 Total Patients Enrolled
~13 spots leftby Jun 2026